Jose Masdeu
Neurology · Bethesda, MDNPI 1376853770
Payments from drug & device makers
Across 403 payments — averaging $14,453 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2.6M
- Biogen$1.4M
- AbbVie$872K
- Eisai Inc.$787K
- Novartis$105K
- Lilly USA, LLC$41K
- plus $27K from 31 others
Across 10 payments — averaging $4248.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$42K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 42 | $2,588,231 |
| Biogen | 34 | $1,403,158 |
| AbbVie | 64 | $872,185 |
| Eisai Inc. | 74 | $787,333 |
| Novartis | 8 | $105,273 |
| Lilly USA, LLC | 59 | $41,130 |
| Acadia Pharmaceuticals Inc | 15 | $11,718 |
| Avanir Pharmaceuticals, Inc. | 13 | $10,722 |
| GE HealthCare | 7 | $2,560 |
| Alnylam Pharmaceuticals Inc. | 8 | $377 |
| CSL Behring | 9 | $193 |
| Otsuka America Pharmaceutical, Inc. | 8 | $164 |
| Siemens Medical Solutions USA, Inc. | 1 | $113 |
| Amgen | 8 | $110 |
| Fujirebio Diagnostics, Incorporated | 2 | $108 |
| Merz North America, Inc. | 6 | $104 |
| Sanofi | 6 | $98 |
| Amneal Pharmaceuticals LLC | 1 | $95 |
| Genentech, Inc. | 3 | $85 |
| Corium, LLC | 3 | $74 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Lundbeck LLC | 3 | $59 |
| AstraZeneca | 2 | $46 |
| Grifols USA, LLC | 3 | $42 |
| Neurocrine Biosciences, Inc. | 3 | $42 |
| Tanabe Pharma America, Inc. | 3 | $35 |
| Catalyst Pharmaceuticals, Inc. | 2 | $30 |
| C2n Diagnostics, LLC | 1 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $29 |
| Amylyx Pharmaceuticals, Inc. | 1 | $26 |
| Life Molecular Imaging Ltd | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| GRT US Holding, Inc. | 1 | $17 |
| Argenx US, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| UCB, Inc. | 1 | $15 |
How this compares
$5,824,395 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Bethesda
- Pavel KleinBethesda$3.2M
- Jonathan RossBethesda$1.4M
- John WernerBethesda$410K
- Matthew EdwardsonBethesda$219K
- Ellen MowryBaltimore$5.7M
- Daniel BeckerLutherville$4.2M
- Michael PolydefkisBaltimore$4.1M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.